SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as community members rally around the project's culture and real-world partnerships, including its sponsorship of a pro MMA fighter. The community is actively discussing the coin's potential and coordinated efforts to 'slap' the bears.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Recent community interest in Fresenius Medical Care (FMS) stems from potential applications of DefenCath in dialysis and discussions around mortality benefits and infection prevention, particularly in comparison to competitors. Discussions also highlight an upcoming earnings report and its growth potential, with some suggesting it's undervalued, while others point to rising costs pressuring near-term results. Acquisition and partnership strategies are seemingly driving growth, but regulatory concerns persist in the dialysis and healthcare services sector.

Pop Cat refers to a series of videos in which using an image of a cat named Oatmeal, the cat is photoshopped as if it's opening its mouth wide in an O shape.

Popcat

POPCAT is trending as the community anticipates further gains, drawing comparisons to DOGE and SHIB, with some suggesting it could reach new all-time highs. Bullish sentiment is fueled by positive market vibes and accumulation, with predictions of a strong climb and some pointing to a potential test of resistance levels. Community members express optimism about the meme coin's potential within the Solana ecosystem, viewing it as a promising investment.

SSgA Active Trust - The Energy Select Sector SPDR Fund

Energy Select Sector SPDR Fund

The energy sector, represented by $XLE, is experiencing heightened volatility amidst geopolitical tensions and speculation around OPEC+ production decisions. Community discussions center on the potential for both short squeezes and longer-term gains, weighing factors like global demand, supply disruptions, and the impact of tariffs on the energy market. Traders are actively monitoring technical indicators and news events for directional cues, with some highlighting a possible rotation into energy amid broader market uncertainty.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending amid discussions around short-term bullish setups and potential targets, with community members actively debating entry points and whether recent price movements signal a continuation of its upward trend or a possible pullback. The coin is also tied into AI discussions, with community members exploring it's relationship with the emerging sector. Recent news of the coin being listed on a new exchange is potentially contributing to the increased interest.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is trending as investors assess if the semiconductor rally can continue, with some analysts pointing to overbought conditions and potential for a correction. Community members are debating the impact of AI spending, the potential for a chip glut, and revenue projections for chip manufacturers. Bullish sentiment remains due to the AI buildout, while others warn of bubble-like conditions reminiscent of the dot-com era.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as investors digest recent Q4 earnings forecasts and a planned workforce reduction, leading to price target cuts from analysts. The community is discussing potential bottom fishing opportunities, while also weighing the impact of macro headwinds and potential tariff implications. Despite concerns, some remain bullish on ON's long-term prospects in the EV and AI data center markets.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to positive momentum, fueled by strong revenue growth and optimism surrounding upcoming earnings, with the community discussing potential price targets and buyout scenarios. Community members are highlighting the company's solid fundamentals and pipeline, particularly Recorlev, while anticipating positive EPS. Bullish sentiment is driven by high growth expectations and potential upside from the XP-8121 program.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending amid discussions about its potential in the AI chip market and recent news regarding a possible antitrust probe in China, leading to community debate on its valuation and competitive positioning against Nvidia and AMD.  Bullish investors believe Qualcomm is undervalued and poised for growth in AI, pointing to its partnerships and low P/E ratio, while others express skepticism about its ability to compete effectively and highlight potential headwinds from regulatory issues and customer relationships. The community is closely watching for further developments in AI and potential catalysts.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve is trending amid anticipation for potential cannabis rescheduling, spurred by comments from President Trump regarding a decision in the coming weeks. Community discussions revolve around the potential for significant gains, the impact on MSOs, and comparisons to Canadian LPs, while some caution against over-optimism. A potential Florida recreational vote in 2026 is also a key talking point for long term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire ANDOVER, Mass., Oct. 31, 2025...

Here's Why TransMedics (TMDX) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

TMDX Stock Falls Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y

TransMedics posts surging profit and higher revenues on strong OCS and logistics growth, yet its shares slide despite upbeat Q3 results. 

<ul class="summary-bullets"><li>TransMedics shares fell 9% in after-hours trading after its third-quarter results showed strong year-over-year growth but a sequential slowdown and margin pressure.</li><li>The company reaffirmed full-year 2025 guidance and outlined expansion plans, including a 22-aircraft U.S. fleet and a new European logistics network launching in Italy next year.</li><li>Retail traders on Stocktwits viewed the selloff as a buying opportunity, with several predicting a rebound toward $135–$150.</li></ul>Retail chatter around TransMedics Group surged on Thursday after the company’s shares fell 9% in after-hours trading, as investors focused on a sequential slowdown and margin pressure that overshadowed otherwise strong year-over-year growth in the company’s third-quarter (Q3) earnings.<h2 class="st-heading-2">Seasonal Dip Tempers A Strong Quarter</h2>The organ transplant technology company's Q3 revenue was $143.8 million, an increase of 32% over the same period a year ago, but down from $157.4 million in the second quarter (Q2) due to normal seasonal patterns in transplant volumes. U.S. transplant revenue increased 32% to $139 million, and international revenue increased 41% to $3.6 million, primarily driven by heart procedures.Gross margin slipped to 59% from 61.4% in Q2, which the company attributed to international expansion costs and seasonality. Operating income came in at $23.3 million, below the previous quarter’s $36.6 million, while net income dropped to $24 million or $0.71 per share, compared with $1.03 in Q2.<h2 class="st-heading-2">Guidance&nbsp;</h2>TransMedics reaffirmed its 2025 full-year revenue outlook of $595–$605 million, implying 36% growth at the midpoint, and said gross margins are expected to remain near 60% over the next few years.The company expanded its air logistics fleet to 22 aircraft, covering about 78% of U.S. organ transport missions, and plans to pilot a double-shift system to boost utilization in early 2026. It also plans to launch its first European transplant logistics network in Italy next year, adapting its U.S. model for regional regulations.Clinical momentum continues, with next-generation heart and lung trials expected to begin enrollment in the fourth quarter, pending full FDA clearance by early 2026.<h2 class="st-heading-2">Stocktwits Traders Call TransMedics Pullback A Buying Opportunity</h2>On Stocktwits, retail sentiment for TransMedics Group was ‘extremely bullish’ amid a 1,175% surge in 24-hour message volume.One user said they planned to keep adding shares of TransMedics until the stock reached $150, calling the pullback a buying opportunity.<stembedurl>https://stocktwits.com/stephen19/message/634232623</stembedurl>Another described it as a “hardcore dip buy,” predicting the stock would soon rebound to around $135.<stembedurl>https://stocktwits.com/healthcareguru/message/634218541</stembedurl><a href="https://stocktwits.com/symbol/TMDX">TransMedics Group’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of TransMedics Group Inc. (NASDAQ: TMDX), a medical technology company focused on organ transplant therapy, on July 28, 2025. (Photo illustration by Cheng Xin/Getty Images)

Retail Traders Swarm TransMedics After Q3 Print— Retail Bulls Call It A ‘Hardcore Dip Buy’

TransMedics shares fell 9% in after-hours trading after its third-quarter results showed strong year-over-year growth but a sequential slowdown and margin pressure.

Equity

TransMedics (TMDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for TransMedics (TMDX) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

TransMedics (TMDX) Beats Q3 Earnings Estimates

TransMedics (TMDX) delivered earnings and revenue surprises of +78.38% and -0.76%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

TransMedics Reports Third Quarter 2025 Financial Results

TransMedics Reports Third Quarter 2025 Financial Results TransMedics Reports Third Quarter 2025 Financial Results PR Newswire ANDOVER, Mass., Oct. 29, 2025 ANDOVER, Mass., Oct. 29, 2025 /PRNewswire...

TransMedics (TMDX) Reports Next Week: Wall Street Expects Earnings Growth

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025

TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025 TransMedics to Report Third Quarter 2025 Financial Results on October 29, 2025 PR Newswire ANDOVER, Mass., Oct. 15, 2025...

TMDX Partners With Mercedes-Benz to Launch Organ Transport Network

TransMedics collaborates with Mercedes-Benz to launch Italy's first organ transport network, expanding its OCS model beyond the United States.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.38	--	--	N/A
Q3 '25	$0.36	$0.66	83.06%	BEAT
Q2 '25	$0.45	$0.92	104.44%	BEAT
Q1 '25	$0.26	$0.70	165.21%	BEAT
Q4 '24	$0.16	$0.19	19.06%	BEAT

TMDX
Transmedics Group Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest TMDX News

TMDXTransmedics Group Inc